Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 129

Similar articles for PubMed (Select 24895099)

1.

Sodium glucose co-transporter 2 inhibitors: a novel approach to the management of type 2 diabetes mellitus.

Davis CS, Fleming JW, Warrington LE.

J Am Assoc Nurse Pract. 2014 Jul;26(7):356-63. doi: 10.1002/2327-6924.12135. Epub 2014 Jun 4.

PMID:
24895099
2.

Perspective: SGLT2 inhibitors may predispose to ketoacidosis.

Taylor SI, Blau JE, Rother KI.

J Clin Endocrinol Metab. 2015 Jun 18:jc20151884. [Epub ahead of print]

PMID:
26086329
3.

A SYSTEMATIC REVIEW ON EFFECT OF CANAGLIFLOZIN IN SPECIAL POPULATION.

Patel S, Gohel K, Patel BG.

Curr Diabetes Rev. 2015 Jun 18. [Epub ahead of print]

PMID:
26084476
4.

In brief: ketoacidosis with SGLT2 inhibitors.

[No authors listed]

Med Lett Drugs Ther. 2015 Jun 22;57(1471):94. No abstract available.

PMID:
26079766
5.
6.

C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.

Ding Y, Mao L, Xu D, Xie H, Yang L, Xu H, Geng W, Gao Y, Xia C, Zhang X, Meng Q, Wu D, Zhao J, Hu W.

Bioorg Med Chem Lett. 2015 Jul 15;25(14):2744-8. doi: 10.1016/j.bmcl.2015.05.040. Epub 2015 May 27.

PMID:
26026363
7.

The role of empagliflozin in the management of type 2 diabetes by patient profile.

Hedrington MS, Davis SN.

Ther Clin Risk Manag. 2015 May 5;11:739-49. doi: 10.2147/TCRM.S71762. eCollection 2015. Review.

8.

Extra-glycaemic properties of empagliflozin.

Solini A.

Diabetes Metab Res Rev. 2015 May 20. doi: 10.1002/dmrr.2666. [Epub ahead of print]

PMID:
25994513
9.

Therapy: SGLT2 inhibitor dapagliflozin promotes glucagon secretion in α islet cells.

Sargent J.

Nat Rev Endocrinol. 2015 Jul;11(7):382. doi: 10.1038/nrendo.2015.70. Epub 2015 May 5. No abstract available.

PMID:
25942656
10.

Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus.

Liakos A, Karagiannis T, Bekiari E, Boura P, Tsapas A.

Ther Adv Endocrinol Metab. 2015 Apr;6(2):61-7. doi: 10.1177/2042018814560735. Review.

11.

[The position of new antidiabetics in clinical practice: SGLT2 vs DPP4 inhibitors].

Šoupal J, Prázný M.

Vnitr Lek. 2015 Apr;61(4):291-4. Czech.

PMID:
25894256
12.

The Novel Role of the Kidney in Diabetes Management: Sodium-Glucose Co-Transporter 2 Inhibitors.

Swislocki AL, Jialal I.

Metab Syndr Relat Disord. 2015 Apr 20. [Epub ahead of print]

PMID:
25893855
13.

The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.

Whalen K, Miller S, Onge ES.

Clin Ther. 2015 Jun 1;37(6):1150-66. doi: 10.1016/j.clinthera.2015.03.004. Epub 2015 Apr 16. Review.

PMID:
25891804
14.

Short-term impacts of sodium/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events.

Yabe D, Nishikino R, Kaneko M, Iwasaki M, Seino Y.

Expert Opin Drug Saf. 2015 Jun;14(6):795-800. doi: 10.1517/14740338.2015.1034105. Epub 2015 Apr 7.

PMID:
25851664
15.

Benefits, risks of SGLT2 inhibitors explored at session.

Caffrey MK.

Am J Manag Care. 2014 Jul;20(10 Spec No):E11. No abstract available.

PMID:
25830192
16.

Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors.

Wu SH, Yao CH, Hsieh CJ, Liu YW, Chao YS, Song JS, Lee JC.

Eur J Pharm Sci. 2015 Jul 10;74:40-4. doi: 10.1016/j.ejps.2015.03.011. Epub 2015 Mar 27.

PMID:
25819489
17.
18.

Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease.

Zanoli L, Granata A, Lentini P, Rastelli S, Fatuzzo P, Rapisarda F, Castellino P.

ScientificWorldJournal. 2015;2015:317507. doi: 10.1155/2015/317507. Epub 2015 Feb 15. Review.

19.

Case Reports That Illustrate the Efficacy of SGLT2 Inhibitors in the Type 1 Diabetic Patient.

Bell DS.

Case Rep Endocrinol. 2015;2015:676191. doi: 10.1155/2015/676191. Epub 2015 Feb 16.

20.

SGLT2 inhibitors: the latest "new kids on the block"!

Cefalu WT, Riddle MC.

Diabetes Care. 2015 Mar;38(3):352-4. doi: 10.2337/dc14-3048. No abstract available.

PMID:
25715412
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk